Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

Pediatric Infectious Disease Journal

Volumn 17, Issue 3, 1998, Pages 217-224

  Piedra, Pedro A ^a,c   Grace, Susan ^a,c   Jewell, Alan ^a,c   Spinelli, Susan ^a,c   Hogerman, Deborah A ^b,c   Malinoski, Frank ^b,c   Hiatt, Peter W ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Wyeth Lederle Vaccines   (United States)

^c North American Biologicals Inc   (United States)

Author keywords

Cystic fibrosis; Purified fusion protein vaccine; Respiratory syncytial virus

Indexed keywords

NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SODIUM CHLORIDE; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HN PROTEIN; HUMANS; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0031894642     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199803000-00009     Document Type: Article

References (22)

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
2. Selwyn BJ (BOSTID Researchers). The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev Infect Dis 1990;12:S870-87.
3. Wang EEL, Law BJ, Stephens D, and other members of PICNIC. Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J. Pediatr 1995;126:212-19.
4. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol 1996;17:163-8.
5. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
6. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Child 1990;144:346-8.
7. Pohl C, Green M, Wald ER, Ledesma-Medina J. Respiratory syncytial virus in pediatric liver transplant recipients. J Infect Dis 1992;165:166-9.
8. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93.
9. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995;21:376-9.
10. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza infections in the hospitalized elderly. J Infect Dis 1995;172:389-94.
11. CDC. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(RR-5):1-24.
12. Hiatt P. Respiratory viral infections in cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH, eds. Cystic fibrosis: current topics. Chichester, UK: Wiley, 1994:211-33.
13. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996;15:23-31.
14. Anderson LJ, Parker RA, Strikas RL. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 1990;161:640-6.
15. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163:693-8.
16. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med 1993;329:1524-30.
17. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995;8:22-33.
18. Johnson PR, Collins PL. The fusion glycoproteins of human respiratory syncytial virus of subgroups a and b: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 1988;69:2623-8.
19. Hamill PVV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979;32:607-29.
20. Frisancho AR. New norms of upper limb fat and muscle area for assessment of nutritional status. Am J Clin Nutr 1981; 34:2540-5.
21. Piedra PA, Glezen WP, Kasel JA, et al. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 1995;13:1095-101.
22. Dowell SF, Anderson LJ, Gary HE, et al. Respiratory syncytial virus is an important cause of community acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996;174:456-62.